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Abstract
The S-type lectin galectin-9 binds to the negative regulatory molecule Tim-3 on T cells and induces their apoptotic deletion
or functional inactivation. We investigated whether galectin-9/Tim-3 interactions contribute to the deletion and exhaustion
of the antiviral T cell response in chronic hepatitis B virus infection (CHB). We found Tim-3 to be expressed on a higher
percentage of CD4 and CD8 T cells from patients with CHB than healthy controls (p,0.0001) and to be enriched on
activated T cells and those infiltrating the HBV-infected liver. Direct ex vivo examination of virus-specific CD8 T cells binding
HLA-A2/peptide multimers revealed that Tim-3 was more highly upregulated on HBV-specific CD8 T cells than CMV-specific
CD8 T cells or the global CD8 T cell population in patients with CHB (p,0.001) or than on HBV-specific CD8 after resolution
of infection. T cells expressing Tim-3 had an impaired ability to produce IFN-c and TNF-a upon recognition of HBV-peptides
and were susceptible to galectin-9-triggered cell death in vitro. Galectin-9 was detectable at increased concentrations in the
sera of patients with active CHB-related liver inflammation (p = 0.02) and was strongly expressed by Kupffer cells within the
liver sinusoidal network. Tim-3 blockade resulted in enhanced expansion of HBV-specific CD8 T cells able to produce
cytokines and mediate cytotoxicity in vitro. Blocking PD-1 in combination with Tim-3 enhanced the number of patients from
whom functional antiviral responses could be recovered and/or the strength of responses, indicating that these co-
inhibitory molecules play a non-redundant role in driving T cell exhaustion in CHB. Patients taking antivirals able to potently
suppress HBV viraemia continued to express Tim-3 on their T cells and respond to Tim-3 blockade. In summary, both Tim-3
and galectin-9 are increased in CHB and may contribute to the inhibition and deletion of T cells as they infiltrate the HBV-
infected liver.
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Introduction
Galectin-9 is one of a family of soluble b-galactoside–binding
proteins that have been reported to have a multifactorial role in T
cell development and homeostasis [1]. When first described, it was
noted to be abundantly expressed in foetal and adult murine liver
[2]. It was also found to be heavily expressed in the thymus, where
it was proposed to play a role in deleting developing thymocytes
[2]. Galectin-9 binds to T cell immunoglobulin and mucin
domain-containing molecule (Tim-3), which was initially identified
as a membrane protein on terminally differentiated T helper type
1 (Th1) T cells [3]. Tim-3/galectin-9 interactions have been found
to drive death of Th1 T cells and promote peripheral tolerance
[4]. More recently, Tim-3 has been recognised to also have the
potential to contribute to the functional inactivation of CD8 T
cells in persistent viral infections [5,6].
The antiviral T cell response in patients with chronic HBV
infection (CHB) is markedly depleted and prone to apoptosis [7].
The few residual T cells bear the hallmark of profound exhaustion,
with high expression of the co-inhibitory receptors PD-1 [8] and
CTLA-4 [9] and poor effector function [8,10]. Tim-3 has been
reported to mark those T cells that have progressed to advanced
stages of the hierarchical impairment of effector function
characteristic of T cell exhaustion, defined by loss of IFN-c
production [5,6]. We therefore postulated that Tim-3 would be
upregulated on the exhausted T cells in patients with CHB, which
have often been exposed to decades of extremely high antigenic
load.
We further hypothesised that galectin-9/Tim-3 interactions
might be of particular relevance in HBV infection because it
targets the liver. In a mouse model of acute graft versus host
disease, CD8 T cells in the liver were noted to have particularly
high Tim-3 expression; blockade of Tim-3 suggested it played an
important part in the maintenance of hepatic tolerance [11]. The
original description of galectin-9 being preferentially expressed in
the liver and localised close to the sinusoids [2], suggested that it
could be ideally positioned to promote deletion or functional
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inactivation of Tim-3-expressing HBV-specific CD8 T cells as they
infiltrate the site of infection. In this study we report that Tim-3 is
upregulated on both CD4 and CD8 T cells in CHB, particularly
the intrahepatic fraction. HBV-specific T cells with impaired
production of IFN-c and TNF-a have increased Tim-3 expression
and blockade results in recovery of functionally active T cells. The
ligand, galectin-9, is upregulated in patients with active disease
and is highly expressed by the Kupffer cell population in the
hepatic sinusoids.
Results
Increased Tim-3 Expression on Global T Cells from
Patients with CHB
In order to assess the potential role of Tim-3 in CHB, we first
examined expression of the glycoprotein Tim-3 directly ex vivo by
flow cytometry on PBMC from 26 CHB and 17 healthy
individuals (Table 1). Consistent with previous observations [12],
we found elevated frequencies of Tim-3-expressing global CD8 T
cells in individuals with CHB compared to healthy controls
(median of 21.2 versus 10.1 respectively, p,0.0001) (Figure 1a, c).
There was a non-significant trend towards a higher frequency of
Tim-3+ expressing CD8 T cells in CHB patients with high
(.2000 IU/ml) versus low (,2000 IU/ml) HBV DNA (data not
shown). The frequency of Tim-3+ CD8 T cells did not correlate
with with eAg status (data not shown) but showed a stepwise
increase with increasing liver inflammation (as assessed by ALT
level, Figure 1c). Tim-3 expression was also elevated on global
CD4 T cells in HBV infected individuals relative to uninfected
controls (p,0.0001) and correlated with ALT (Figure 1b, d),
although it was expressed at a lower overall frequency than on
CD8 T cells. In keeping with this global increase in Tim-3
expression, there was an increase in T cells expressing the
activation marker CD38 in CHB (Figure S1a); Tim-3 expression
was enriched on this activated fraction (Figure 1c, d).
In order to investigate whether Tim-3-expressing T cells were
enriched in the intrahepatic compartment, the site of HBV
replication, we obtained paired liver biopsies and blood samples
from 8 patients with CHB. We isolated intrahepatic lymphocytes
(IHL) and compared the expression of Tim-3 on global CD8 and
CD4 T cells from the liver and blood of the same patients. A
higher frequency of Tim-3 expressing T cells was seen in the
intrahepatic compartment in every case for both CD8 and CD4 T
cells (p = 0.003 and p= 0.004 respectively (Figure 1e, f, Figure
S1b); this may reflect enhanced induction at the site of disease or
preferential liver tropism of Tim-3 expressing cells.
Up-regulation of Tim-3 on HBV-specific CD8+ T Cells with
Impaired Effector Function and Apoptotic Propensity
Having observed an upregulation of Tim-3 on global T cells
from chronically infected individuals, we then looked at the
expression of this negative regulator on HBV-specific T cells.
Using a panel of HBV and CMV HLA-A2/peptide multimers, we
assessed Tim-3 expression on the surface of HBV and CMV-
specific CD8 T cells detectable ex vivo in PBMC samples from 24
patients with CHB (Table S1), 6 patients who had resolved HBV
and 6 healthy volunteers (Figure 2a, b). The frequency of HBV-
specific CD8 T cells expressing Tim-3 was significantly higher
than the global CD8 population in the same patients (p,0.001,
Figure 2c). Tim-3 expressing HBV-specific CD8 T cells were
increased in patients with CHB (regardless of VL or ALT, data not
shown) compared to those who had resolved infection successfully
(p,0.001, Figure 2d). We also observed significantly higher
expression of Tim-3 on HBV-specific compared to CMV-specific
CD8 T cells in patients with CHB (p= 0.001)(Figure 2d). For 17
patients with CHB we were able to examine paired HBV and
CMV-specific CD8 T cell responses, confirming higher frequen-
cies of Tim-3-expressing CD8 T cells directed against HBV than
CMV epitopes within the same patients (p,0.001, Figure 2e).
CMV-specific CD8 T cells in HBV-infected subjects showed a
trend towards higher Tim-3 expression than CMV-specific CD8 T
cells in resolved or healthy controls, (Figure 2d), in line with the
global upregulation of Tim-3 on global T cells in CHB.
Previous studies of patients with chronic HIV [6] and HCV [5]
infection have described impaired effector function of Tim-3-
expressing CD8 T cells. We therefore assessed the functionality of
Tim-3+ HBV-specific CD8 T cells, focusing on their production of
the cytokines IFN-c and TNF-a, which have been shown to be
able to purge HBV from infected hepatocytes [13]. PBMC were
labelled with a panel of HLA-A2/peptide multimers representing
well-described HLA-A2-restricted HBV epitopes, stimulated with
a pool of peptides of the same specificities and stained for their
ability to produce IFN-c or TNF-a. As reported previously [14],
there was a small multimer-negative population of CD8 able to
produce cytokines upon stimulation with HBV peptides (Figure 3a,
Figure S1c). CD8 T cells able to bind HLA-A2/HBV peptide
multimers but unable to produce IFN-c expressed higher levels of
Tim-3 than those cells that retained the capacity to produce IFN-c
upon encounter with cognate peptide (p = 0.005) (Figure 3a,b,
Figure S1c). Likewise, those HBV-specific responses able to
produce TNF-a had reduced expression of Tim-3 (Figure 3c).
Tim-3 expression therefore defines a population of dysfunctional T
cells in the context of chronic HBV infection.
Engagement of Tim-3 by its ligand, galectin-9, has also been
shown to reduce IFN-c production by inducing death of Th1 T
cells [4]. We therefore evaluated the potential of this interaction to
dampen immune responses through induction of cell death in the
context of CHB. PBMC from patients with CHB were cultured in
Figure 1. Tim-3 is up-regulated on peripheral and intrahepatic T cells in HBV infection. PBMC from 26 HBV infected and 17 uninfected
subjects were stained with antibodies against CD3, CD4, CD8, CD38 and Tim-3 or an isotype-matched control Ig. Representative flow cytometry data
for (a) CD8 and (b) CD4 T cells from a patient with CHB and a healthy subject. Tim-3 expression on global (c) CD8 and (d) CD4 T cells from healthy
individuals and patients with CHB, shown as compiled data and stratified according to ALT level or CD38 co-expression. Expression of Tim-3 on (e)
CD8 and (f) CD4 of paired PBMC and IHL from 8 patients with CHB. For all figures, statistical analyses were performed using Mann-Whitney test or the
Wilcoxon rank test for paired data; only significant p values (p,0.05) are indicated. Horizontal bars denote medians.
doi:10.1371/journal.pone.0047648.g001
Table 1. Patient clinical characteristics.
CHB (n=111) Healthy (n=20) Resolved (n=6)
Gender Male = 61 Male = 9 Male = 4
Age (years) 33 (21–68) 33 (20–47) 37 (28–43)
ALT (IU/L) 44 (10–1208) NA NA
HBV DNA (log IU/ml) 3.6 (1.3–9.1) NA NA
eAntigen + n= 31 NA NA
*Median and range shown.
**NA not applicable.
doi:10.1371/journal.pone.0047648.t001
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the presence of recombinant galectin-9 or media alone for 6 hours.
A fluorescent probe able to bind active caspases (FLICA) was
added for the last hour of culture and cells were then stained for
the death marker 7AAD (Figure 3d). Although CD4 and CD8 T
cells showed high levels of baseline apoptosis/death as reported
previously in patients with CHB [7,9], there was a variable further
increase in expression of active caspases and 7AAD, suggesting
galectin-9 mediated induction of both early/late apoptosis and cell
death (Figure 3d, e). When the cells were co-cultured in the
presence of both galectin-9 and soluble Tim-3 chimera, there was
partial blocking of death induction (Figure S2a).
The Tim-3 Ligand Galectin-9 is Expressed by Kupffer Cells
and its Secretion is Increased in Active CHB
The natural ligand for Tim-3, galectin-9, was originally
reported to be preferentially expressed in the liver [2]. We
therefore postulated that Tim-3-expressing HBV-specific CD8 T
cells encounter their ligand as they infiltrate the liver, the site of
HBV replication. Frozen and paraffin-embedded sections of liver
biopsies from patients with CHB (Table 2) were stained with a
polyclonal galectin-9 antibody. We observed a high intensity of
pan-lobular galectin-9 staining in all the sections from 8 HBV
infected individuals, localising in sinusoids with a pattern
suggestive of Kupffer cell expression (Figure 4a). Three-colour
immunoflourescence combining galectin-9 with CD68 confirmed
co-localisation of the majority of the intense galectin-9 staining
with Kupffer cell (CD68) staining (Figure 4b). Expression of
galectin-9 by CD14+CD68+ cells was further demonstrated by
flow cytometry of freshly isolated Kupffer cells (Figure 4c).
Galectin-9 is a member of a large family of carbohydrate-
binding lectins that lack signal sequences for conventional
extracellular transport but are secreted by a non-classical pathway
[1]. To assess whether HBV infection upregulates galectin-9,
secreted levels circulating in patients with different levels of CHB
disease activity were compared with those in healthy controls.
There was a step-wise increase in circulating levels of galectin-9
according to disease activity (Figure 4d). Patients with biochemical
evidence of highly active CHB-related liver disease (ALT.100 U/
L) had significantly higher levels of serum galectin-9 than CHB
patients with ALT,50 IU/L, (p = 0.01) or healthy controls
(p = 0.02).
Blocking Tim-3/galectin-9 Interactions Increases
Functional HBV-specific T Cell Responses and is
Complementary to PD-1 Blockade
To further define the contribution of Tim-3 expression to the
dysfunction of HBV-specific T cells, we investigated the impact of
blocking this pathway in vitro. To do this we used a recombinant
Tim-3 Fc chimera to compete for galectin-9 and block the
interaction of this ligand with Tim-3 expressed by T cells. Using
this approach we were able to rescue additional CD8 T cells able
to produce IFN-c or TNF-a in response to stimulation with HBV
peptides in 17 out of 32 (53%) and 17 out of 28 (64%) patients with
CHB respectively (Figure 5). In 15/28 patients Tim-3 blockade
resulted in the reconstitution of dual IFN-c/TNF-a producing
CD8 T cells (data not shown). Functional HBV-specific CD8 T
cell responses could also be enhanced using a Tim-3-blocking
mAb (kindly provided by V Kuchroo, Figure S2b).
Blockade of another co-inhibitory receptor, PD-1, has already
been shown to rescue some HBV-specific CD8 T cell responses
[8]. Tim-3-expressing cells were present in both the PD-1
positive and PD-1 negative HBV-specific CD8 T cell populations
(Figure S3a), suggesting some overlap in the role of these co-
inhibitory receptors. To explore whether PD-1 and Tim-3 played
complementary roles in mediating T cell exhaustion in CHB we
compared the effect of single or dual PD-1 and Tim-3 blockade
on HBV-specific CD8 T cell responses. Virus-specific T cells
were expanded with a pool of HBV peptides in the presence of
Tim-3 Fc chimera, PDL1/2 blocking mAb, both or control IgG
and analysed for the proportion of CD8 T cells producing IFN-c
and/or TNF-a (Figure 5a, 6a, b). Roughly equal proportions of
the patient cohort responded to either of these approaches with
the recovery of IFN-c-producing CD8 T cells. Responders to
Tim-3 or PD- L1/2 single blockade were largely not overlapping,
suggesting non-redundant roles for Tim-3 and PD-1 (Figure 6a).
Dual Tim-3 and PD- L1/2 blockade had an additive or
synergistic effect on the recovery of HBV-specific CD8 T cells
in some patients. This was most marked for TNF-a producing
CD8 T cells, that were augmented by dual blockade in 12 out of
28 patients tested, significantly more than were rescued by either
Tim-3 or PD-L1/2 blockade alone (Figure 6b, Figure S3b).
We then assessed the ability of Tim-3 blockade to enhance
the expansion of CD8 T cells with cytotoxic potential by
measuring their degranulation upon stimulation with HBV
peptides. We found that 7 out of 8 patients showed enhanced
cytolytic activity of HBV-specific CD8 T cells following Tim-3
blockade in culture (Figure S3c). In this smaller cohort, Tim-3
was more effective than PD- L1/2 blockade at rescuing cytolytic
function of HBV-specific CD8 T cells (p,0.05, Figure 3d). The
IL-2 producing capacity of CD8 T cells was also enhanced in 4
out of 9 patients (Figure S3e,f).
In a subset of 16 of the 28 patients in whom Tim-3 blockade was
carried out, HBV responses were assessed using a pool of
overlapping peptides spanning the HBV core protein, allowing
the additional assessment of virus-specific CD4 responses (Figure
S4a). A partial recovery of T cell function was also observed for
CD4 T cells, with 11 out of 16 patients showing increased IFN-c
responses, 9 out of 16 increased TNF-a and 9 out of 9 increased
IL-2 (Figure S4b,c,d). There was considerable overlap in
responsiveness to Tim-3 and PD-1 blockade for CD4 T cells but
five patients showed enhanced recovery of both IFN-c and TNF-
aCD4 responses upon dual compared to single blockade (Figure
S5a, b). Of note, Tim-3 blockade alone was more effective at
rescuing IL-2 producing CD4 responses than PD-1 blockade alone
or in combination (Figure S5c, d).
Figure 2. Tim-3 expression is increased on HBV-specific T cells. HLA-A2+ healthy controls and CHB patients were stained ex vivo with HLA-A2
multimers presenting the CMV-pp65 epitope NLVPMVATV (HLA-A2/NLVP) or a combined panel of 6 HBV-multimers (HLA-A2/core 18–27, envelope
183–191, envelope 348-, envelope 335-,polymerase 455-, polymerase 502-) and with anti-Tim-3 mAb or its isotype. Representative FACS plots from
two patients with CHB showing staining for HBV (a) and CMV (b) multimers and Tim-3 expression on gated multimer–specific CD8 T cells compared
to an isotype control mAb. (c) Compiled data showing the frequency of virus-specific (multimer+) and global CD8 T cells expressing Tim-3 directly ex
vivo in 24 CHB patients. (d) Compiled data showing the frequency of HBV and CMV-specific CD8 T cells expressing Tim-3 directly ex vivo in healthy
controls (n = 6), patients with CHB (n = 24) and patients who had resolved HBV (n = 6). (e) Ex-vivo staining in 17 individuals with CHB in whom paired
responses could be analysed with both HBV and CMV multimers.
doi:10.1371/journal.pone.0047648.g002
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Tim-3 and PD-1 Contribute to Residual T Cell Exhaustion
upon Potent Viral Load Reduction
Despite the ability of antiviral therapy to maintain viral
suppression, this strategy alone is unable to reconstitute a durable
antiviral T cell response [9,15]. We investigated the role of Tim-3-
mediated T cell co-inhibition in CHB patients starting antiviral
therapy. In a cross sectional analysis we explored the expression of
Tim-3 on global T cells from HBV infected individuals treated
with antiviral therapy compared to our cohort of untreated
patients. A non-significant trend to a lower frequency of Tim-3
expressing T cells was noted in patients on therapy (Figure 7a). To
further explore this observation, we analysed 3 patients longitu-
dinally from the time of initiation of antiviral therapy for more
than one year into their antiviral regimen (Table 3). In two
patients, Tim-3 expression increased on CD4 and CD8 T cells
prior to starting treatment and did not fall below baseline levels on
therapy, despite HBV DNA becoming undetectable. A third
patient showed a progressive decrease in Tim-3 expression on
CD4 and CD8 T cells accompanying the decline in viraemia seen
upon initiation of antiviral therapy (Figure 7b). The incomplete
reduction in Tim-3 expression is in line with the ongoing
production of large amounts of sAg and persistent expression of
other markers of T cell exhaustion in patients on antiviral
treatment [9].
Having shown that Tim-3 can continue to be expressed on CD8
and CD4 T cells from individuals receiving antiviral treatment, we
then examined whether HBV-specific T cells were still amenable
to rescue by blocking Tim-3/galectin-9 interactions in vitro in
these patients. CD8 T cells producing IFN-c and/or TNF-a were
still reconstituted by Tim-3 blockade in 2 out of 3 patients at the
last on-treatment follow-up time point, when they had received at
least 15 months of therapy. Similarly PD- L1/2 blockade
continued to have an effect on CD8 T cell reconstitution in
patients with effective viral load suppression. By contrast there was
no further recovery of CD4 responses to Tim-3 blockade in 3 out
of 3 patients and to PD- L1/2 blockade in 2 out of 3 patients by
the last on-treatment follow-up time point (Figure 7c).
Discussion
T cell responses are tightly regulated by multiple mechanisms in
order to maintain homeostasis and prevent excessive inflammation
within the immune system. Whilst these feedback mechanisms are
important to allow termination of successful acute immune
responses, they can excessively constrain antiviral immunity in
the setting of persistent viral infections. This paradox is
particularly evident in the liver, where the highly tolerising
environment is likely to have evolved to preserve the functional
integrity of this vital organ in the face of the high antigenic load it
receives through the portal venous system [16]. Co-inhibitory
pathways such as PD-1 are critical to hepatic tolerance and are
further upregulated in viral hepatitis, contributing to the failure of
T cell control of hepatic pathogens such as HBV and HCV. In this
study we showed that co-inhibitory interactions between Tim-3
and galectin-9 are also activated in HBV infection and disable
antiviral T cell immunity.
We found a higher expression of Tim-3 on global T cells,
particularly the activated fraction, in patients with CHB compared
to healthy controls and further enrichment of this co-inhibitory
receptor within the liver-infiltrating fraction. Amongst circulating
CD8 T cells, Tim-3 expression was significantly increased on the
HBV-specific fraction compared to the generalised CD8 T cells or
to CMV-specific CD8 T cells within the same patients. HBV-
specific CD8 T cells expressing Tim-3 were associated with clinical
outcome, since patients who had resolved HBV infection had
significantly lower levels. Previous studies in patients persistently
infected with HIV or HCV infection have shown that Tim-3
expression on T cells marks a highly dysfunctional subset of cells
characterised by impaired production of antiviral cytokines such as
IFN-c and TNF-a and poor proliferative capacity. Similarly, we
found that HBV-specific T cells that were unable to secrete these
cytokines following short-term stimuli expressed higher levels of
Figure 3. Tim-3 expressing HBV-specific T cells are dysfunctional. PBMC derived from HLA A2+ patients with CHB were stained with a panel
of HLA-A2/HBV multimers and then were stimulated overnight with a pool of HBV peptides of matched specificity to the multimers, followed by
intracellular staining for IFN-cor TNF-a. (a) Representative histograms showing levels of Tim-3 (black line) or isotype binding (grey shading) on CD8 T
cells binding HLA-A2/HBV peptide multimers or producing IFN-c upon encounter with HBV peptides. (b) Compiled data from 10 patients with CHB.
(c) Tim-3 expression on CD8 T cells binding HLA-A2/HBV peptide multimers or producing TNFa upon stimulation with HBV peptides. (d) FACS plots
and (e) summary data showing the induction of caspases (FLICA) and 7AAD in CD8 and CD4 T cells with or without the addition of galectin-9. Active
caspases, indicating apoptosis, were determined using a fluorescent-labelled inhibitor of polycaspases (FAM-VAD-FMK, FLICA), and death was
identified by 7AAD stain. Early apoptotic events are indicated in the lower right quadrant (FLICA+7AAD2), late apoptotic events in the right upper
quadrant (FLICA+7AAD+) and necrotic cells in the left upper quadrant (7AAD+FLICA-). ‘Total death’ was estimated by summing events in these 3
quadrants.
doi:10.1371/journal.pone.0047648.g003
Table 2. Clinical details of patient who underwent liver biopsy and galectin-9 quantification from serum samples.
Sera Histology
CHB (n=34) Healthy (n =10) CHB (n=8) Healthy (n =5)
Gender Male = 19 Male = 6 Male = 6 Male = 3
Age 34 (21–68) 31 (24–47) 47 (29–67) 45 (27–66)
ALT (IU/L) 53.5 (11–1208) NA 52 (22–189) 25 (8–120)
HBV DNA (log IU/ml) 4.6 (1.4–9.12) NA 4.4 (1.4–7.2) NA
eAg status eAg+= 12 NA eAg+= 5 NA
*Median and range shown.
**NA not applicable.
doi:10.1371/journal.pone.0047648.t002
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Tim-3. In addition to functional inactivation, interaction between
Tim-3 and its ligand, galectin-9, may promote deletion of T cells,
as evidenced by the induction of T cell death seen following this
interaction in vitro. The ability of galectin-9 to trigger T cell death
via Tim-3 is well-described, although the mechanisms remain
poorly defined [17].
Whether the predominant effects of Tim-3/galectin-9 inteac-
tions in patients with CHB are deletion or inactivation, the
functional relevance of this ligand/receptor interaction is support-
ed by the recovery of HBV-specific T cells with effector function
following in vitro blockade. In more than half of our cohort of CHB
subjects we were able to show some reversal of exhaustion in
HBV-specific T cells, detecting an increase in cytokine producing
cells following in vitro Tim-3 pathway blockade. We also observed
an expansion of CD8 T cells with enhanced cytotoxic function
when PBMC were co-cultured with anti-Tim-3 blocking agent, in
line with recent findings in HCV infection [18]. The expansion of
functional HBV-specific T cells in some, but not all, of our cohort
supports the role of Tim-3 in T cell exhaustion, but also highlights
the contribution of co-inhibitory receptors to their dysfunction
[8,9]. As reported previously [9], blockade of one or more
inhibitory receptors can paradoxically diminish virus-specific
responses in some cases, perhaps due to activation-induced cell
death. The fact that Tim-3 blockade, like blockade of PD-1 or
CTLA-4, cannot uniformly rescue responses is in line with the
heterogeneity of HBV infection and the multiple layers of co-
regulation characteristic of T cell exhaustion [19]. Our data
showing a non-redundant role for Tim-3 and PD-1 in HBV are in
line with previous reports showing that Tim-3 and PD-1 either
mark distinct [6] or overlapping populations [5] of exhausted T
cells in HIV and HCV infection respectively. A recent study of
in vivo Tim-3/PD-1 blockade further demonstrated their synergis-
tic cooperation in restraining T cell-mediated control of LCMV
[20].
The ligand for Tim-3, galectin-9, is known to be a secreted
protein, externalised by non-classical mechanisms [1]. In line
with recent findings in HCV [21], we observed significantly
elevated levels of galectin-9 in the circulation of those patients
with HBV-related liver inflammation and also noted strong
staining in Kupffer cells. A recent study has also reported
galectin-9 expression on Kupffer cells (and weaker expression on
dendritic cells) in the setting of hepatocellular carcinoma [22].
Kupffer cells are specialised, hepatic-resident macrophages that
line the liver sinusoids. Galectin-9 expressing Kupffer cells are
therefore ideally positioned to mediate deletion or functional
inactivation of Tim-3 expressing T cells as they percolate slowly
through the narrow and extensive intrahepatic circulatory bed.
Systemic infusion of galectin-9 can inhibit the T cell responses
driving immunopathology in herpes simplex virus infection [23].
Likewise, elevated levels of galectin-9 released in to the
circulation of patients with CHB, perhaps as a feedback
response to liver inflammation, could contribute to the
maintenance of tolerance in T cells once they have left the
galectin-9-rich environment of the liver sinusoids.
Galectin-9 can exert its inhibitory effect on T cells not only
directly but also via the induction of other regulatory populations,
including granulocytic myloid-derived suppressor cells MDSC
[24] and Tregs [21,23] that may expand preferentially because of
their resistance to Tim-3-mediated apoptosis induction [23].
Future studies should therefore investigate whether galectin-9-
expressing Kupffer cells can induce analogous regulatory popula-
tions augmenting the extrinsic regulation of antiviral immunity in
the HBV-infected liver. Additional complexity has been added by
the recent demonstration that Tim-3-galectin-9 interactions can
also alter the function of the cells producing galectin-9; Tim-3-
expresing T cells induced bactericidal activity in galectin-9
expressing macrophages infected with TB [25] and galectin-9
induced pro-inflammatory cytokine production by monocytes
from HCV-infected livers [21]. Interventions to block the Tim-3
pathway could exert a potent reversal of the residual Tim-3-
mediated immunosuppression that our data suggest persists in
patients with CHB on antiviral treatment. However the potential
application of Tim-3 blockade would need to take into consider-
ation the bidrectional role of this pathway in regulating the
balance between immunity and immunopathology and in
promoting bacterial defense within macrophages.
Materials and Methods
Study Population
Clinical assessment and blood sampling were performed during
routine hepatitis clinics, with written informed consent and local
ethical board approval of the Royal Free Hospital, the Royal
London Hospital and Camden Primary Care Ethics Review
Boards. A total of 111 patients with CHB, 6 patients with resolved
HBV and 20 healthy volunteers participated in the study; there
were no significant differences in their demographics (Table 1). All
the subjects were HCV and HIV seronegative. Patients with CHB
were stratified by HBV DNA levels above or below 2,000 IU/mL
(determined by real-time polymerase chain reaction [PCR]),
according to European Association for the Study of the Liver
guidelines [26]. Three patients with CHB were followed longitu-
dinally after commencing lamivudine and adefovir (Table 3).
Paired peripheral blood and liver biopsy specimens (surplus to
diagnostic requirements) were obtained from eight patients with
CHB (Table 2).
Flow Cytometric Analysis of Total and Virus-specific CD8
and CD4 T Cells
PBMC were isolated from whole blood by Ficoll-Hypaque
density gradient centrifugation; intrahepatic lymphocytes were
isolated as previously described [9]. For analysis of total CD8 and
CD4, cells were surface-stained with mAb anti-CD3 Pe-Cy7, CD8
Alexa700, CD4 APC-Cy7 (eBioscience), Tim-3 PE (R&D) or
isotype matched control (R&D) in the presence of fixable live/
dead stain (Invitrogen). In order to optimise the detection of low
frequency HBV-specific T responses directly ex vivo, cells were
stained with a combined pool of human leukocyte antigen A2
HBV dextramers (HLA-A2)/c18–27, HLA-A2/e183–191, HLA-
A2/e335–343, HLA-A2/e348–357,HLA-A2/p455-) and HLA-
A2/p502-) (Immudex). CMV-specific CD8 T cells were detected
Figure 4. The Tim-3 ligand galectin-9 is expressed by Kupffer cells, and its secretion is increased in active CHB. Immunohistochemistry
of a section from a cryopreserved CHB liver biopsy stained with a polyclonal galectin-9 antibody (shown in brown) at 10X and 40X magnification. (b)
Immunofluorescence of a section from a cryopreserved CHB liver biopsy stained with DAPI (blue, left panel), anti-CD68 mAb (green, central panel)
and galectin 9 polyclonal antibody (red, right panel). Double positive staining is indicated in yellow in the lower panel. (c) Kupffer cells were isolated
from 4 liver explants and stained with CD14, CD68 and galectin-9 or its isotype. Representative histograms show galectin-9 staining on CD14+CD68+
fraction compared to isotype-matched control. (d) Galectin-9 levels were analysed in the serum of 10 healthy subjects and 42 CHB patients: 16 with
ALT,50, 17 with ALT 50–100 and 9 with ALT .100 (mean and SEM shown).
doi:10.1371/journal.pone.0047648.g004
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Figure 5. Blocking the Tim-3 pathway can increase the frequency of IFNc and TNFa-producing HBV-specific CD8 T cells. (a)
Representative dot plot showing recovery of HBV-specific CD8 T cells responses (IFN-c, TNF-a) in a patient with CHB. PBMC were stimulated with
peptides and cultured for 10 days in the presence of soluble Tim-3 FC chimera, PDL1/L2 blocking antibody or both. Summary data of the effect of
blocking Tim-3 on IFN-c (b) and TNF-a (c) production by CD8 T cells in response to HBV peptides.
doi:10.1371/journal.pone.0047648.g005
Figure 6. Non-redundant roles for Tim-3 and PD-L1/2 blockade in recovery of functional HBV-specific T cell responses. Summary data
from 28 patients with CHB of the percent of HBV-specific CD8 T cells producing IFN-c (a) or TNF-a (b) upon blockade of Tim-3 (red bars), PDL1/L2
(green bars) or dual Tim-3 and PDL1/L2 (blue bars), compared to stimulation with peptides without blocking (white bars).
doi:10.1371/journal.pone.0047648.g006
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by HLA-A2/NLVPMVAYV pentamers (Proimmune) or A2/
NLVPMVAYV dextramer (Immudex). Co-staining with Tim-3
mAb did not alter the percent of CD8 T cells able to bind
dextramers (Table S1). B cells were stained with anti-CD19-V500
(ebioscience) and were excluded from the analysis of dextramer
positive CD8 T cells. Where stated, virus-specific CD8 T cells
expressing Tim-3 were stained with HBV dextramers before being
stimulated with HBV peptides (10 mM) or control for 6 hours in
the presence of 1 ug/ml Brefeldin A. For analysis of virus-specific
T cells producing IFN-g and TNF-aor degranulation, the cells
were first stained with CD107a PE and then permeabilised and
fixed in one step (BD-cytofix ) followed by intracytokine staining
with mAb anti-IFN-c-APC (or Pacific blue) (eBioscience) and
TNF-a-PE (BD).
Cells were acquired on a LSRII (BD Biosciences) and analyzed
using Flowjo.
Peptides
HLA-A2 negative patients were stimulated with a pool of 15mer
peptides overlapping by 10 residues (OLP) spanning core of HBV
genotype D. HLA-A2 positive individuals were stimulated with a
panel of peptides representing immunodominant HLA-A2 re-
stricted epitopes from HBV (envelope: FLLTRILTI,
WLSLLVPFV, LLVPFVQWFV, GLSPTVWLSV; core:
FLPSDFFPSV; polymerase: GLSRYVARL, KLHLYSHPI),
CMV pp65 (NLVPMVATV).
Assays of HBV-specific T Cell Function after in vitro
Blockade
To examine the effect of blocking inhibitory pathways, PBMC
were stimulated with or without HBV peptides (1 mM) in presence
of Tim-3 FC chimera (R&D System) (2 mg/mL ), PD-L1, PD-L2
(eBioscience), or control IgG (BD-Biosciences) (5 mg/mL) or both
Tim-3 FC chimera and PD-L1,PD-L2. Cells were cultured for 10
days, supplemented with 20 U/mL IL-2 at 0 and 4 days,
restimulated at day 9 with 1 mM HBV peptide for 16 hours in
the presence of 1 mg/mL Brefeldin A (Sigma-Aldrich), and
identified by intracellular staining for IFN-c, TNF-a and IL2.
To assess degranulation function, CD107a antibody was added at
the time of the restimulation at day 9.
Flow Cytometric Analysis of Apoptosis and Cell Death
PBMC from patients with CHB were stimulated with 5 ug/ml
recombinant galectin-9 for 6 hours at 37uC in the presence or
absence of soluble Tim-3 FC chimera (R&D System) (2 mg/mL) or
media alone. Carboxyfluorescein-FLICA (FAM-VAD-FMK) re-
agent was added during the last hour of culture. The degree of
pancaspase activation was determined using the carboxyfluor-
escein-FLICA apoptosis detection kit (Serotec) according to the
manufacturer’s protocol for detection by flow cytometry. Cells
were also co-stained with anti-CD3 Pe-Cy7, CD8 Alexa700, and
CD4 APC-Cy7 (eBioscience). 7-amino-actinomycin D (7-AAD)
stain was used to label dead cells prior to acquisition.
Galectin-9 ELISA
Serum samples (Table 2) were stored at280. Plate ELISA assay
for the detection of Galectin-9 was carried out according to
manufacturer’s instructions (Uscn, Life Science Inc.).
Immunohistochemistry and Immunofluorescence
Sections from paraffin-embedded and cryopreserved liver
biopsies (Table 2) were stained for galectin-9. After being
deparaffinized in xylene and rehydrated in a graded series of
ethanol, paraffin embedded sections were rinsed in distilled water.
An antigen retrieval step was performed by microwaving at 900W
for 20 minutes in Tris EDTA buffer pH9. Alternatively
Figure 7. Effect of antiviral treatment on Tim-3 expression and response to Tim-3 blockade. (a) Tim-3 expression on global CD3 CD4+ T
cells and CD3 CD8+ T cells. Each dot represents an individual data point (12 healthy, 26 CHB, 6 CHB on antivirals with undetectable viral load);
horizontal lines represent the mean. (b) Percent of CD4 (square), CD8 (triangle) T cells expressing Tim-3 (left y axis) and HBV load circle, right y axis)
plotted longitudinally for 3 patients starting antiviral therapy. (c) PBMC sampled at the indicated time points from these three individuals were
stimulated for ten days with HBV OLP with control IgG, Tim-3 Fc chimera, anti-PDL1/PDL2 antibodies or both. Bars represent the % of HBV-specific
CD8 T cells producing IFN-c or TNF-a following blockade after subtracting the frequency detectable without any blockade.
doi:10.1371/journal.pone.0047648.g007
Table 3. Clinical characteristics of patients followed up longitudinally.
Patient Time point HBV DNA (log IU/ml) ALT (IU/L) eAg status Gender Age
1 5 months pre-Tx 5.62 116 neg Male 39
3 months pre-Tx 3.77 500 neg
3 months post-Tx 1.40 40 neg
15 months post Tx 1.40 46 neg
19 months post-tx 1.40 47 neg
2 7 months pre-Tx 6.15 58 pos Male 63
2 months pre-Tx 6.4 53 pos
5 months post-Tx 3.10 207 pos
15 months post-Tx 1.40 15 pos
3 4 months pre-Tx 4.86 405 neg Male 47
3 months pre-Tx 1.40 33 neg
7 months post-Tx 1.40 27 neg
15 months post-Tx 1.40 30 neg
doi:10.1371/journal.pone.0047648.t003
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cryopreserved HBV sections were air dried and washed in buffer
prior to staining. Prior to incubation with the primary antibody,
sections were blocked for endogenous peroxidase, washed gently in
buffer, blocked with Serum Blocking Reagent and further treated
with Avidin and Biotin Blocking Reagents (R&D Systems;
Minneapolis, MN). The goat polyclonal galectin-9 antibody
(R&D Systems; Minneapolis, MN) was used at a dilution of
1:100 for frozen and 1:300 for paraffin embedded biopsies for
overnight incubation at 4uC. A Cell & Tissue Staining Goat Kit
HRP DAB system (R&D Systems; Minneapolis, MN) was used for
antibody detection. All staining steps were performed according to
the manufacturers instructions. Visualization was achieved with
DAB Chromogen solution followed by counterstaining with
Mayer’s hematoxylin.
Immunostaining of cryopreserved sections from HBV infected
liver biopsies was performed using a combination of the following
primary antibodies Galectin-9 goat polyclonal IgG (R & D
Systems) and CD68 mouse monoclonal (KP1, Abcam). Sections
were incubated with Protein Block Serum Free (Dako) for 20 min
at room temperature and then incubated overnight with primary
antibodies diluted in PBS. Sections were then washed with PBS
and stained with the appropriate secondary antibodies: Rabbit
anti-goat Alexa Fluor 546 and donkey anti-mouse Alexa Fluor 488
(1:500, Invitrogen) for 45 min at room temperature in the dark.
Sections were washed and mounted with Vectashield mounting
medium with DAPI (Vector Laboratories Inc). In the absence of a
primary antibody no immunoreactivity was detected. Images were
captured using a Zeiss Axioskop 2 plus microscope and AxioVision
imaging.
Kupffer Cell Isolation and Staining
Kupffer cells were isolated from liver sections as previously
described [27]. Briefly, liver was digested using collagenase IV and
DNase I, homogenised in a stomacher at low intensity and layered
onto a density gradient (Optiprep 17%). The kupffer cell-rich
fraction was plated onto a flat-bottom 6-well plate in DMEM with
10% FBS; non-adherent cells were washed off 2 hours post-
plating. Adherent cells were trypsinised and co-stained ex vivo with
mAb anti-CD14 V500 (BD) and Galectin-9 PE (Biolegend) or
isotype matched control (Biolegend). Cells were then permeabi-
lised and fixed in one step (BD-cytofix) followed by intracellular
cytokine staining with mAb anti-CD68 FITC (eBioscience). Data
was acquired on a LSRII (BD Biosciences) and analyzed using
Flowjo.
Statistical Methods
Mann Whitney test was used to compare differences between
patient groups. Comparison between paired samples was carried
out by Wilcoxon signed rank test. A P value of less than 0.05 was
considered significant. Prism 4.0 software was used for all analysis.
Supporting Information
Figure S1 CD38 expression, intrahepatic Tim-3 expres-
sion and controls for multimer staining. (a) Summary data
showing CD38 expression on CD8 and CD4 T cells from CHB
patients stratified according to their level of liver inflammation
(ALT). (b) Representative FACS plots comparing Tim-3 expres-
sion on global CD8 (upper panel) and CD4 (lower panel) T cells
from paired patient PBMC and intrahepatic lymphocyte (IHL)
samples. Gating for Tim-3 was based on its isotype control for
each sample. (c) Representative example of CD8 T cells stained
with HBV multimers, a control multimer (bound with an
irrelevant peptide) or no multimers directly ex vivo without
stimulation (upper panel) or after peptide stimulation (lower
panel).
(TIF)
Figure S2 Effects of galectin-9 and sTim-3 Fc chimera
and Tim3 blocking mAb. (a) FACS plots showing the
induction of caspases (FLICA) and 7AAD in CD8 and CD4 T
cells with or without the addition of galectin-9+/2 sTim-3 Fc
chimera. (b) Representative dot plots comparing recovery of HBV-
specific CD8 T cells responses (IFN-c) with different Tim-3
blocking approaches in two patients with CHB. PBMC were
cultured in media alone or stimulated with HBV peptides in the
presence of control IgG, Tim-3 blocking mAb or soluble Tim-3 Fc
chimera.
(TIF)
Figure S3 Impact of Tim-3/PD-1 blockade on effector
function of HBV-specific CD8. (a) Summary data of the
expression of Tim-3 on PD1+ and PD1- HBV-specific T cells. (b)
Percent of HBV-specific CD8 T cells producing TNF-a following
in vitro co-culture with HBV peptides and control IgG (white
bars), soluble Tim-3 Fc chimera (red bars), PDL1/L2 blocking
antibodies (green bars) and dual blockade (blue bars) in 28 CHB
subjects studied (mean +2/SEM). Bar charts showing percent of
CD8 T cells expressing CD107 (c) or IL-2 (e) after culture with
HBV peptides in the presence of Tim-3 Fc chimera (red bars)
compared to control IgG (white bars) in each patient with CHB.
Background expression in unstimulated wells was subtracted.
Summary data of percent of HBV-specific CD8 T cells expressing
CD107 (d) or IL-2 (f) following in vitro co-culture with HBV
peptides and control IgG (white bars), soluble Tim-3 Fc chimera
(red bars), PDL1/L2 blocking antibodies (green bars) and dual
blockade (blue bars).
(TIF)
Figure S4 Blocking the Tim-3 pathway can increase the
frequency of IFN-c,TNF-a and IL2 producing HBV-
specific CD4 T cells. (a) Representative dot plots showing
recovery of HBV-specific CD4 T cell responses (IFN-c, TNF-a)
following culture with HBV OLP in the presence of soluble control
IgG, Tim-3 Fc chimera, PDL1&L2 blocking antibody or both for
10 days. Summary data on the effect of blocking Tim-3 (red bars)
on IFN-c (b), TNF-a (c) and IL-2 (d) production by CD4 T cells in
response to HBV OLP compared to HBV stimuli without
blockade (white bars). The background expression of IFN-c,
TNF-a and IL2 in unstimulated wells was subtracted.
(TIF)
Figure S5 Comparison of Tim-3/PD-1/dual blockade
on HBV-specific CD4 T cell effector function. Summary
data on the effect of blocking Tim-3 (red bars), PD-1 (green bars)
or both pathways (blue bars) on IFN-c (a), TNF-a (b) and IL2 (c)
production by CD4 T cells in response to HBV OLP in patients
with CHB. The bars represent the % of HBV-specific CD4 T cells
producing cytokines following blockade after subtracting the
frequency detectable without any blockade. (d) Summary bar
charts of impact of blocking Tim-3, PD-1 or both on IL-2
production in response to HBV-specific peptides.
(TIF)
Table S1 Frequency of HBV and CMV multimer
staining cells (in the presence of Tim-3 or Tim-3 isotype
mAb).
(DOCX)
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